Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2014-01-13 |
Galapagos (Belgium) |
€ 2.9 million |
grant |
Flemish Agency for Innovation by Science and Technology (IWT) (Belgium) |
Rare diseases - Genetic diseases |
Grant |
2014-01-10 |
Atara Biotherapeutics (USA - CA) |
$52 million |
series B financing round |
Amgen Ventures (USA - CA) Celgene (USA - NJ) EcoR1 Capital (USA - CA) Alexandria Venture Investments (USA - CA) DAG Ventures (USA - CA) Domain Associates (USA - CA) Kleiner Perkins Caufield & Byers (USA - CA) The Baupost Group (USA - MA) |
Cancer - Oncology - Kidney diseases - Renal diseases |
Series B financing round |
2014-01-09 |
AC Immune (Switzerland) |
CHF 20 million (€16.1 million) |
series D financing round |
|
Neurodegenerative diseases |
Series D financing round |
2014-01-08 |
Apitope (UK) and Grave's consortium (GSK Vaccines, Quintiles and KWS Biotest) |
€ 6 million |
grant |
European Commission’s Seventh Framework Program (FP7) |
Allergic diseases - Immunological diseases |
Grant |
2014-01-08 |
eoStrep, a consortium consisting of Lund University (Sweden), MinervaX (Denmark), CiToxLAB A/S (Denmark), and BioKinetic Europe Ltd. (UK) |
€ 6 million |
grant |
European Commission’s Seventh Framework Program (FP7) |
Infectious diseases |
Grant |
2014-01-08 |
MinervaX (Denmark) |
DKK 22 million (€ 3 million) |
|
|
Infectious diseases |
Fundraising |
2014-01-07 |
Isarna Therapeutics (Germany) |
€ 13 Million |
fundraising |
AT NewTec (Germany), MIG-managed funds (Germany) |
Cancer - Oncology |
Fundraising |
2014-01-06 |
Scancell Holdings (UK) |
£80,000 (€ 96,318) |
grant |
Nottingham City Council (UK) |
Cancer - Oncology |
Grant |
2013-12-30 |
TopiVert (UK) |
|
fundraising |
Imperial Innovations (UK) |
Gastrointestinal diseases - Digestive diseases - Inflammatory diseases - Ophtalmological diseases |
Fundraising |
2013-12-24 |
Oramed Pharmaceuticals (Israel) |
$15.8 million |
private placement |
|
Metabolic diseases |
Private placement |
2013-12-23 |
Tigenix (Belgium) |
€ 10 million |
loan |
Kreos Capital (UK) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
Loan |
2013-12-19 |
Epigenomics (Germany - USA) |
€ 2.5 million |
private placement |
|
Diagnostic - Cancer - Oncology |
Private placement |
2013-12-17 |
Crescendo Biologics (UK) |
£17.5 million (€20.7 million) |
series A financing round |
Innovations (UK), Astellas Venture Management (Japan), Sofinnova Partners (France) |
Cancer - Oncology - Inflammatory diseases |
Series A financing round |
2013-12-17 |
BIO-INSPIRE consortium (Fujifilm (The Netherlands) ISTEC (Italy), Erasmus Medical Center (The Netherlands), Medicyte (Germany), Fraunhofer Institute (Germany), Bone Therapeutics (Belgium) and Universita di Bologna (Italy) |
€3.8 million |
Marie Curie grant |
European Commission’s Seventh Framework Program (FP7) |
Bone diseases - Regenerative medicine |
Grant |
2013-12-17 |
Atara Biotherapeutics (USA - CA) |
$38.5 million |
series B financing round |
Amgen Ventures (USA - CA) Celgene (USA - NJ) EcoR1 Capital (USA - CA) Alexandria Venture Investments (USA - CA) DAG Ventures (USA - CA) Domain Associates (USA - CA) Kleiner Perkins Caufield & Byers |
Cancer - Oncology - Kidney diseases - Renal diseases |
Series B financing round |
2013-12-16 |
Neovacs (France) |
|
equity line |
|
Allergic diseases - Immunological diseases |
Credit line |
2013-12-11 |
BrainStorm Cell Therapeutics (USA - Israel) |
$800,000 (€ 582,114) |
grant |
Office of the Chief Scientist (OCS -Israel) |
Neurodegenerative diseases |
Grant |
2013-12-11 |
Ario Pharma (UK) |
£1.9 million (€ 2.27 million) |
fundraising |
New Science Ventures, Forbion Capital Partners and Seroba Kernel Life Sciences. |
Respiratory diseases - Inflammatory diseases |
Fundraising |
2013-12-09 |
Gecko Biomedical (France) |
€8 million |
series A financing round |
Omnes Capital (France) CM-CIC Capital Finance (France) CapDecisif Management (France) |
Medical devices |
Series A financing round |
2013-12-04 |
AMCARE (Advanced Materials for CArdiac REgeneration) consortium (AdjuCor (Germany), Cardio3Biosciences (Belgium), Contipro (Czech Republic), Explora BioTech (Italy), Innova (Italy), Trinity College Dublin (Ireland), the Fraunhofer Institute for Interfacial Engineering and Biotechnology (Germany), the Eberhard Karls Universitat Tübingen (Germany) Boston Scientific based in Galway, Ireland) |
€8.7 million |
grant |
European Commission’s Seventh Framework Program (FP7) |
Cardiovascular diseases |
Grant |